Human respiratory syncytial virus cost-effectiveness of therapy: Difference between revisions
No edit summary |
m Changes made per Mahshid's request |
||
Line 11: | Line 11: | ||
[[Category:Mononegavirales]] | [[Category:Mononegavirales]] | ||
[[Category:Needs content]] | [[Category:Needs content]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] |
Latest revision as of 18:03, 18 September 2017
Human respiratory syncytial virus Microchapters |
Differentiating Human Respiratory Syncytial Virus from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Human respiratory syncytial virus cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Human respiratory syncytial virus cost-effectiveness of therapy |
FDA on Human respiratory syncytial virus cost-effectiveness of therapy |
CDC on Human respiratory syncytial virus cost-effectiveness of therapy |
Human respiratory syncytial virus cost-effectiveness of therapy in the news |
Blogs on Human respiratory syncytial virus cost-effectiveness of therapy |
Directions to Hospitals Treating Human respiratory syncytial virus |
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.